文献速递脑血管病认知障碍与痴呆

社区样本中波士顿标准2.0版诊断脑淀粉样血管病的敏感性与特异性

Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample.
PubMed 文献 · Neurology · 2023-12-13

研究在社区队列中评估波士顿标准2.0版诊断脑淀粉样血管病的准确性。纳入134例有生前3T MRI和详细病理数据的死者,其中49例为病理证实的肯定病例。2.0版敏感性38.8%、特异性83.5%,较1.0/1.5版敏感性提高12.3%但特异性降低5.9%;在 probable CAA 中,严格脑叶皮层微出血数量在真阳性与假阳性间有差异(p=0.004)。

要点

  • 社区样本中波士顿标准2.0版诊断CAA的敏感性为38.8%,特异性为83.5%。
  • 与1.0/1.5版相比,2.0版敏感性提高12.3%但特异性降低5.9%。
  • 在 probable CAA 中,严格脑叶皮层微出血数量真阳性高于假阳性(p=0.004)。

核心结论

  • 在社区居住人群中,更新版波士顿标准纳入非出血性神经影像标志物后敏感性提高12.3%、特异性降低5.9%,但诊断敏感性仍然有限。
  • 在 probable CAA 病例中,微出血的皮层位置可能是区分真阳性与假阳性的有前景特征。

研究设计与样本

  • 研究为在芝加哥拉什阿尔茨海默病中心进行的纵向临床-病理老化研究(宗教秩序研究与拉什记忆与老化项目)的参与者。
  • 纳入134例有生前3T MRI和详细病理数据的死者,其中49例为病理证实的肯定CAA病例。
  • 比较当前与早期版本波士顿标准在样本中的诊断效能,并分析 probable CAA 中每种神经影像标志物区分假阳性与真阳性的能力。

主要发现

  • 波士顿标准1.0版与1.5版敏感性相似(均为26.5%),特异性分别为90.6%与89.4%,阴性预测值分别为68.1%与67.9%,阳性预测值分别为61.9%与59.1%。
  • 波士顿标准2.0版敏感性为38.8%,特异性为83.5%。
  • 在按2.0版归类为 probable CAA 的病例中,病理证实的真阳性病例严格脑叶皮层微出血数量高于假阳性病例(p=0.004)。

关键数值与推荐

  • 波士顿标准1.0版:敏感性26.5%,特异性90.6%,阴性预测值68.1%,阳性预测值61.9%。
  • 波士顿标准1.5版:敏感性26.5%,特异性89.4%,阴性预测值67.9%,阳性预测值59.1%。
  • 波士顿标准2.0版:敏感性38.8%,特异性83.5%。
  • 与1.0/1.5版相比,2.0版敏感性提高12.3%,特异性降低5.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The Boston criteria are a set of clinical and neuroimaging features that enable accurate diagnosis of cerebral amyloid angiopathy (CAA) without invasive methods such as brain biopsies or autopsy. The last updates to the Boston criteria, named version 2.0, were recently released and incorporated new nonhemorrhagic MRI features. These criteria have been validated in symptomatic samples, with improved diagnostic yield. We set out to investigate the accuracy of the Boston criteria v2.0 for the diagnosis of CAA in a community-based sample. METHODS: Participants were recruited from longitudinal clinical-pathologic studies of aging conducted at the Rush Alzheimer's Disease Center in Chicago: the Religious Orders Study and the Rush Memory and Aging Project. Deceased participants with in vivo 3T MRI and detailed pathologic data available were included in the analysis. We compared the diagnostic yield of the current and earlier versions of the Boston criteria in our sample. Among those classified as probable CAA according to the Boston criteria v2.0, we investigated the ability of each neuroimaging marker to distinguish between false-positive and true-positive cases. RESULTS: In total, 134 individuals were included in the study (mean age = 82.4 ± 6.0 years; 69.4% F), and 49 of them were considered pathology-proven definite cases with CAA (mean age = 82.9 ± 6.0 years; 63.3% F). The Boston criteria versions 1.0 and 1.5 yielded similar sensitivity (26.5%, both), specificity (90.6% and 89.4%, respectively), and predictive values (negative: 68.1% and 67.9%; positive: 61.9% and 59.1%, respectively). The recently released Boston criteria v2.0 offered higher sensitivity (38.8%) and slightly lower specificity (83.5%). Among those classified as probable CAA (v2.0), pathology-proven true-positive cases had higher numbers of strictly cortical lobar microbleeds compared with false-positive cases (p = 0.004). DISCUSSION: Similar to findings from symptomatic samples, the inclusion of nonhemorrhagic neuroimaging markers in the updated Boston criteria offered a 12.3% gain in sensitivity among community-dwelling individuals, at the expense of a 5.9% drop in specificity. In cases with probable CAA, the cortical location of microbleeds may represent a promising distinguishing feature between true-positive and false-positive cases. Despite its improved performance, the diagnostic sensitivity of the updated criteria in a community-based sample remains limited. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the Boston criteria v2.0 accurately distinguishes people with CAA from those without CAA.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zanon Zotin MC, Makkinejad N, Schneider JA, et al. Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample. Neurology. 2023. PMID: 38165367. doi:10.1212/WNL.0000000000207940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。